Inhibikase Therapeutics, Inc. (IKT) Financials

NASDAQ Currency in USD Disclaimer

$2.96

south_east -$0 (0%)
Day's range
$2.92
Day's range
$3.05

IKT Income statement / Annual

Last year (2023), Inhibikase Therapeutics, Inc.'s total revenue was $260,500.00, an increase of 111.03% from the previous year. In 2023, Inhibikase Therapeutics, Inc.'s net income was -$19.03 M. See Inhibikase Therapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Operating Revenue $260,500.00 $123,440.00 $3.10 M $698,468.00 $1.12 M $4.04 M $2.06 M $967,386.00
Cost of Revenue $13.62 M $6,723.00 $11.36 M $893,802.00 $2.55 M $3.65 M $1.76 M $846,386.00
Gross Profit -$13.36 M $116,717.00 -$8.26 M -$195,334.00 -$1.43 M $393,847.00 $305,245.00 $121,000.00
Gross Profit Ratio -51.28 0.95 -2.66 -0.28 -1.27 0.1 0.15 0.13
Research and Development Expenses $13.62 M $12.03 M $11.36 M $893,802.00 $2.55 M $3.65 M $1.76 M $846,386.00
General & Administrative Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $2.52 M $0.00 $0.00
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $6.73 M $6.22 M $6.51 M $2.62 M $4.27 M $2.52 M $710,375.00 $734,288.00
Other Expenses -$13.62 M -$123,440.00 -$3.10 M -$698,468.00 -$1.12 M $0.00 $0.00 $0.00
Operating Expenses $6.73 M $18.13 M $14.77 M $2.82 M $5.70 M $2.12 M $2.47 M $734,287.00
Cost And Expenses $20.35 M $18.13 M $14.77 M $2.82 M $5.70 M $2.12 M $2.47 M $1.58 M
Interest Income $1.06 M $74,453.00 $19,923.00 $29,402.00 $24,835.00 $0.00 $30,945.00 $15,449.00
Interest Expense $0.00 $74,453.00 $19,923.00 $29,402.00 $24,835.00 $30,332.00 $0.00 $0.00
Depreciation & Amortization $177,398.00 $6,723.00 $14.77 M $2.82 M $5.70 M $2.12 M $405,130.00 $613,288.00
EBITDA -$19.91 M -$18.12 M -$14.77 M -$2.82 M -$5.70 M $0.00 $0.00 $0.00
EBITDA Ratio -76.44 -146.81 -4.76 -4.04 -5.08 -0.53 -0.2 -0.02
Operating Income Ratio -77.12 -146.86 -4.76 -4.04 -5.08 -0.53 -0.2 -0.63
Total Other Income/Expenses Net $1.06 M $74,453.00 -$19,923.00 -$29,402.00 -$24,835.00 -$30,332.00 -$30,945.00 -$15,449.00
Income Before Tax -$19.03 M -$18.05 M -$14.79 M -$2.85 M -$5.72 M -$2.15 M -$436,075.00 -$628,737.00
Income Before Tax Ratio -73.05 -146.26 -4.77 -4.08 -5.1 -0.53 -0.21 -0.65
Income Tax Expense $0.00 -$148,906.00 $19,923.00 $29,402.00 $24,835.00 -$161,141.00 -$405,130.00 -$15,449.00
Net Income -$19.03 M -$17.91 M -$14.81 M -$2.88 M -$5.75 M -$2.15 M -$436,075.00 -$628,737.00
Net Income Ratio -73.05 -145.05 -4.78 -4.12 -5.12 -0.53 -0.21 -0.65
EPS -3.57 -4.26 -4.88 -1.72 -3.34 -1.61 -0.25 -0.48
EPS Diluted -3.57 -4.26 -4.88 -1.72 -3.34 -1.61 -0.25 -0.48
Weighted Average Shares Out $5.33 M $4.20 M $3.03 M $1.68 M $1.72 M $1.34 M $1.72 M $1.30 M
Weighted Average Shares Out Diluted $5.33 M $4.20 M $3.03 M $1.68 M $1.72 M $1.34 M $1.72 M $1.30 M
Link